Rosetta Genomics Plans to Raise $6.6M in Direct Offering | GenomeWeb

NEW YORK (GenomeWeb News) – Rosetta Genomics announced after the close of the market on Thursday it has entered into definitive agreements with investors to raise $6.6 million in a direct offering.

The agreement calls for investors to purchase an aggregate of 570,755 ordinary shares at a price of $11.50 per share. The offering is expected to close on or about May 31, the Israel-based molecular diagnostic company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.